Antithrombotic Therapy in High Bleeding Risk, Part I: Percutaneous Cardiac Interventions

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Antithrombotic therapy is crucial after percutaneous coronary interventions (PCI) to prevent thrombotic events.
• However, this therapy increases bleeding risk, which can be severe and outweigh benefits.
• Patient variability in response necessitates identifying high bleeding risk (HBR) individuals for tailored treatment.

Purpose of the Study:

• To review evidence on antithrombotic therapy de-escalation in HBR patients undergoing PCI.
• To provide practical recommendations for optimizing safety and efficacy in this population.
• To address the gap in current guidelines regarding de-escalation strategies for HBR patients.

Main Methods:

• Review of existing literature and clinical trial data on antithrombotic therapy post-PCI.
• Analysis of de-escalation strategies and their impact on bleeding and thrombotic events.
• Synthesis of evidence to formulate clinical recommendations.

Main Results:

• De-escalation of antithrombotic therapy can reduce bleeding complications in HBR patients without compromising efficacy.
• Recent technological advancements facilitate safer de-escalation strategies.
• HBR patients are expected to gain the most benefit from these tailored approaches.

Conclusions:

• Optimizing antithrombotic therapy in HBR patients undergoing PCI is essential for balancing safety and efficacy.
• De-escalation strategies represent a promising approach to mitigate bleeding risk.
• Further guideline development is needed to support these practices.